- Exchange: EN Paris
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Cellectis (ALCLS)
| Open: | 5.6000 | Day's Range: | 5.6000 - 5.7000 | Volume: | 6,000 |
|---|---|---|---|---|---|
| Previous Close: | 5.6100 | 52wk Range: | 4.7100 - 8.0000 | 1-Yr Rtn: | -2.41% |
Key Statistics for ALCLS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. CAC | - |
| Earnings Per Share (ttm) | -1.0470 |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 115.25 |
| Shares Outstanding (M) | 20.43 |
| 30 Day Average Volume | 13,531 |
| Price/Book (mrq) | 1.7490 |
| Price/Sale (ttm) | 5.0994 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 09/20/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ALCLS
Company Profile & Key Executives for ALCLS
Cellectis produces proteins for therapeutic purposes, researches improvements in seed characteristics, and develops treatments against single-gene disorders and against infections by DNA viruses.
| Andre ChoulikaChairman/CEO/Co-Founder | Pierre SchwichChief Financial Officer |
| Jean-Charles EpinatChief Technology Officer | David SourdiveExec VP:Corporate Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ALCLS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page